Learn about key study results presented during ESMO Virtual Congress 2020!
ESMO Video Highlights aim to cover results from a selection of key studies presented during the Congress Science Week-End.
Sunday 20 September
LBA4: IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC), by Johann de Bono
1257O: Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib), by David Hong
LBA41: LEAP-005: Phase 2 Study of Lenvatinib (Len) Plus Pembrolizumab (Pembro) in Patients (Pts) With Previously Treated Advanced Solid Tumors, by Zarnie Lwin
LBA65: The Canadian Cancer Trials Group PA.7 Trial: Results of a Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), by Daniel Renouf
LBA11: IMpassion031: results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC), by Nadia Harbeck
Saturday 19 September
696O_PR: Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase 3 CheckMate 9ER trial, by Toni Choueiri
LBA2: Lorlatinib vs Crizotinib in the First-line Treatment of Patients (pts) with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC): Results of the Phase 3 CROWN Study, by Benjamin Solomon
LBA1: Osimertinib adjuvant therapy in patients (pts) with early stage EGFR mutated (EGFRm) NSCLC after tumour resection (ADAURA): sites of disease recurrence, by Masahiro Tsuboi
LBA18: Overall Survival (OS) Results From SOLAR-1, a Phase 3 Study of Alpelisib (ALP) + Fulvestrant (FUL) for Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced Breast Cancer (ABC) by Fabrice André
LBA17: ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC) by Aditya Bardia
LBA23: Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 by Ajjai Alva
LBA38: Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial by Jean Bourhis
Friday 18 September
LBA21: Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial.s by Christophe Borg